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ABSTRACT
Aims The transition from prison back into the community is particularly hazardous for drug-using offenders whose
tolerance for heroin has been reduced by imprisonment. Studies have indicated an increased risk of drug-related death
soon after release from prison, particularly in the ﬁrst 2 weeks. For precise, up-to-date understanding of these risks, a
meta-analysis was conducted on the risk of drug-related death in weeks 1 + 2 and 3 + 4 compared with later 2-week
periodsintheﬁrst12weeksafterreleasefromprison.Methods English-languagestudieswereidentiﬁedthatfollowed
upadultprisonersformortalityfromtimeof indexreleaseforatleast12weeks.Sixstudiesfromsixprisonsystemsmet
the inclusion criteria and relevant data were extracted independently. Results These studies contributed a total of
69 093 person-years and 1033 deaths in the ﬁrst 12 weeks after release, of which 612 were drug-related. A three- to
eightfold increased risk of drug-related death was found when comparing weeks 1 + 2 with weeks 3–12, with notable
heterogeneity between countries: United Kingdom, 7.5 (95% CI: 5.7–9.9); Australia, 4.0 (95% CI: 3.4–4.8); Washing-
ton State, USA, 8.4 (95% CI: 5.0–14.2) and New Mexico State, USA, 3.1 (95% CI: 1.3–7.1). Comparing weeks 3 + 4
with weeks 5–12, the pooled relative risk was: 1.7 (95% CI: 1.3–2.2). Conclusions These ﬁndings conﬁrm that there
is an increased risk of drug-related death during the ﬁrst 2 weeks after release from prison and that the risk remains
elevated up to at least the fourth week.
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INTRODUCTION
For drug-using offenders, imprisonment can enforce a
substantial reduction in drug use and, as a result, drug
tolerance [1]. Seaman et al. [2] ﬁrst showed that, for a
cohort of 316 male human immunodeﬁciency virus
(HIV)-infected injecting drug-users in Scotland, the rela-
tive risk (RR) of overdose death was eight times higher
[95% conﬁdence interval (CI): 1.5–39.1] in the ﬁrst 2
weeks after release from prison compared with subse-
quent 2-week periods (weeks 3–12). Bird & Hutchinson
[3] reinforced these ﬁndings in their later, Scottish study
of 19 486 male index releases (RR: 7.4, 95% CI: 3.3–
16.3). By not requiring knowledge of prisoners’ injector
status,thisstudyascertainedalldrug-relateddeathsand,
hence, avoided reliance on drug-using prisoners’ willing-
ness to self-identify.
Similarly large studies of prisoners’ mortality post-
release have since been conducted elsewhere, focusing
upon the persistence of increased risk in and beyond the
ﬁrst 2 weeks [4–11]. These mortality studies have used
database linkage as a practical alternative to more tradi-
tional, individually consented prospective cohort studies.
Databaselinkagerequiresminimalinformationabouteli-
gibleex-prisoners,islesscostlyandavoidspotentialbiases
from opt-ins and dropouts.The research team needs only
to specify to a prison service the criteria for eligible
releases. The corresponding registrar of deaths can then
provide the date and cause of death for any person thus
listed.The research team receives a ﬁle, without the need
REVIEW doi:10.1111/j.1360-0443.2010.02990.x
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minimal details as the released prisoner’s age, sex, prison
and date of release and sentence duration—with which
the death information can then be merged.
Index release has been deﬁned variably in the litera-
ture. The most recent release from prison is outcome-
dependent for those who die and so gives biased
ascertainment of deaths [12]. Preferable deﬁnitions of
index release are: either ﬁrst release in a deﬁned accrual
period (as ﬁrst release, unlike last release, is independent
of 12-week survival status) or all releases in a deﬁned
accrual period.
Through meta-analysis [3] of studies of prisoners’
mortality published by August 2009, we have summa-
rized the RR of drug-related death (i.e. overdose or acci-
dental poisoning) in the ﬁrst 2 weeks after release
compared with weeks 3–12 after release.To characterize
furtherthedecayinriskovertime,wehavepooledtheRR
of drug-related death during weeks 1 + 2 and 3 + 4
versus weeks 5–12 after release. This investigation was
designed to update, and make more precise, our under-
standing of the high risk of drug-related death soon after
release from prison.
METHODS
Search strategy
The MEDLINE (January 1966–August 2009) database
was searched using the following combinations of the
Medical Subject Headings (MeSH) terms: illicit/street
drugs and mortality and prisons/ prisoners; prisoners
and mortality/ overdose; prisoners and substance-
related disorders and mortality. The following combina-
tions of text words were also used in the MEDLINE
database and, additionally, in the Google Scholar™
(2009) search engine: prison, release, overdose, drug;
and drug-related deaths, prison, release. These searches
were repeated using alternative expressions for prison,
namely: jail, gaol, custody and incarceration. The result-
ing titles and abstracts were then veriﬁed for suitable
inclusion. The identiﬁed studies were scanned for
further references and their authors were contacted
about published and unpublished studies of which they
were aware.
Inclusion/exclusion criteria
Studies of prisoners’ mortality were eligible for inclusion
if English-language and:
1 Adult prisoners aged 18–35 years were included in
the study (in order to ﬁt the age proﬁle of drug-users
in prisons [13]); and follow-up for mortality was
fromthetimeof indexreleaseforatleast12weeks.The
12-week follow-up period is sufﬁciently long to detect
variations in risk [3].
2 Numbers of drug-related deaths during weeks 1 + 2,
3 + 4 and 5–12 after release could be extracted from
the published literature or by contacting the authors.
3 Drug usage or dependency was not an eligibility crite-
rion for entry into the study. Some individuals at risk
of drug-related death after release may have neither
self-identiﬁed as a drug user nor been diagnosed or
detected as a drug user while in prison. Hence, studies
restricted to prisons’ identiﬁed drug users under-
ascertain the number of drug-related deaths. More-
over, for this identiﬁed subpopulation, the evolution of
risk of drug-related death after release may be differ-
ent.Secondly,theinclusionof non-drugusersdoesnot
affect the RRs of interest which are essentially the
time-adjusted ratio of drug-related deaths.
4 Studies that restrict follow-up to the most recent
release are excluded. Use of most recent release intro-
duces numerator bias by excluding the actual amount
of time spent at liberty after previous releases.
Acceptable deﬁnitions of index release are: either ﬁrst
release in a deﬁned accrual period or all releases in a
deﬁned accrual period (preferably with allowance for
multiplicity).
Data extraction
Drug-related deaths were deﬁned according to the
authors’ deﬁnitions (see Supporting Information, Appen-
dix S1; details at the end).
In the eligible Scottish, Australian and Washington
state studies, the follow-up period started from the
date of index-release until the earliest of date
of death, subsequent incarceration and end of study,
as shown in Table 1. The other eligible studies did not
include a censor mechanism for re-incarcerations.
However, Bird & Hutchinson [3] demonstrated that, in
the absence of this censoring, RRs within 12 weeks of
index release were estimated robustly. Moreover, it is
non-trivial to implement this censoring in jurisdictions
which lack unique prisoner numbers (for example:
England and Wales).
Numbers of drug-related deaths and associated
person-years in weeks 1 + 2, 3 + 4 and 5–12 post-release
were extracted from eligible studies. When not explicitly
available, the author(s) of the study were contacted.
Suitable assumptions, stated in footnotes, were made
if the data could not meet an aspect of the analysis
speciﬁcation.
Statistical analyses
WeevaluatedtheRRof drug-relateddeathbycalculating
the ratio of death rates (deaths relative to person-years)
in:
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son in the research literature;
(ii) weeks 1 + 2 versus weeks 5–12, an expansion of the
ﬁrst comparison that enables us to characterize the
decay in risk over time; and
(iii) weeks 3 + 4 versus weeks 5–12, to verify and quan-
tify the elevation in risk in weeks 3 + 4 after release.
Theassociatedconﬁdenceintervalswerecalculatedas
in the Bird & Hutchinson study [3], where the standard
error of the logarithm of relative risk was derived as:
logarithm of relative risk
chi squareon degreeof freedom
    
-
÷
() 1 ,
where the c2 test was for homogeneity of risk over time
since release.
The heterogeneity between studies was examined
using two methods: ﬁrst, visually by the overlap of the
conﬁdence intervals; and then quantitatively by the
I2 statistic [14]. The I2 statistic measures the impact
of heterogeneity in a meta-analysis and is interpreted
as the proportion of total variation in the estimates
of RR that is due to heterogeneity between studies.
The I2 statistic is preferable to the test for heterogeneity
[15,16], which is poorly powered with few studies to
support its use [17]. Nevertheless, the P-value for this
test has been provided here for reference. Based on these
assessments, pooled estimates of the RRs were made,
where appropriate, using the inverse variance method
[18].
We have also analysed the RRs for deaths from all
causes within 12 weeks of release. The results for this
analysis are not presented in this paper (available from
authors).
RESULTS
Using the above search strategy, we identiﬁed 18 poten-
tiallyrelevantstudies.Of these,12wereexcludedbecause:
(a) studies were of identiﬁed drug-users only (Seaman,
Brettle & Gore [2]; Shewan et al. 2000 [19]; and
Christensen et al. 2006 [12], who could study only
most recent release);
(b) studiesfocusedupondeathsratherthanthefollow-up
of ex-prisoners after release (Harding-Pink, 1990
[20]; Seymour, Oliver & Black, 2000 [21]; Sattar,
2003 [22]]), with one study [22] having considered
mainlydeathsof offendersservinginthecommunity;
(c) two further studies, in addition to Christensen et al.
[13], referred to ex-prisoners’ most recent release
(Stewartet al.2004[23];Rosen,Schoenbach&Wohl
[24]). Fortunately, for one of these studies [23] there
wasalarger,eligiblestudyatthesamefacilitywithan
unbiased deﬁnition of eligible release (Hobbs et al.
2006 [7]); or
(d) the necessary data were not published, and we were
unable to obtain them by contacting the author
(Joukamaa, 1998 [25]; Graham, 2003 [11]; Spauld-
ing, Allen & Stone, 2007 [26]). For two of these
studies [25,26], further examination revealed that
time was measured from the date of prisoners’ recep-
tions rather than their date of release (M. Joukamma
and A. Spaulding, personal communication, 2008
and 2007, respectively).
The ﬁnal exclusion was on grounds of inadequate
power: Verger, 2003 [27] reported only one drug-related
death in the ﬁrst 12 weeks after 1305 prisoner releases.
Figure 1 presents a QUOROM (Quality of Reporting of
Studies retrieved for more 
detailed evaluation (n=18)
Potentially appropriate 
studies to be included in the 
meta-analysis (n=10)
Studies excluded, (n=8). 
Reasons:
-Studies of identified drug users only (n=3)
-Studies focused on deaths versus prisoners’
elapsed time since release (n=3)
-Studies refer to ex-prisoners’ most recent 
releases only (n=2)
Studies included in meta-
analysis (n=6)
Studies excluded, (n=4). 
Reasons:
-Appropriate data were not published and 
unable to obtain from author (n=3)
-Too few drug-related deaths (n=1)
Figure 1 Quality of Reporting of Meta-
analyses (QUOROM) diagram of studies
included and excluded from meta-analysis
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process.
Six studies were included in the ﬁnal analysis [3–10]
as shown in Table 1.
For the six eligible studies, drug-related causes
accounted for 59% of deaths (612 of 1033) within 3
months of release, and 76% within 2 weeks of release
(314 of 411) (Krinsky et al. [11] identiﬁed only ‘deaths
in the state that are sudden, unexpected, violent, or
untimely, or where a person is found dead with an
unknown cause of death’). In total, drug-related deaths
versus other deaths were: 314 versus 97 in the ﬁrst two
weeks and 298 versus 327 in the subsequent period.
Table 2 presents the meta-analyses. For each of the
eligible studies, we provide the numbers of drug-related
deaths and person-years at risk in weeks 1 + 2, 3 + 4 and
5–12 (13 [4–6]) after release from prison. Alongside, we
have the calculated RRs with 95% conﬁdence intervals.
RRs for weeks 1 + 2 versus weeks 3–12 were not pooled
to give an overall estimate. The non-overlapping conﬁ-
dence intervals and large I2 statistic indicate that the
majorityof variation[74%,95%conﬁdenceinterval(CI):
40–88%] in the respective RR estimates is explained by
heterogeneity between studies. Within the United States,
thetwostudieswerealsoconsiderablydifferentfromeach
other (I2 = 75%, 95% CI: -94%). However, pooled RRs,
within countries, for the United Kingdom and Australia
were appropriate and were estimated. The RRs for weeks
1 + 2 versus weeks 5–12 were pooled similarly. The RRs
for weeks 3 + 4, versus weeks 5–12, were sufﬁciently
homogeneous that an overall international estimate
could be made. Figure 2 presents the corresponding
forest plots.
The risk of drug-related death was at least threefold
during weeks 1 + 2 compared with weeks 3–12. The
pooled RR for UK studies was the highest: 7.5 (95% CI:
5.7–9.9), and the lowest was for the Australian studies:
4.0 (95% CI: 3.4–4.8). For the two US studies, the RR
of the Washington State study coincided with the UK
studies (8.4, 95% CI: 5.0–14.2), while the RR of the
New Mexico study was markedly different, but numeri-
cally similar to the Australian studies (3.1, 95% CI: 1.3–
7.1).
The RRs for weeks 1 + 2 versus weeks 5–12 were
ordered similarly, although slightly higher: 9.0 (95% CI:
6.6–12.2) pooled for the United Kingdom and 4.6 (95%
CI:3.8–5.6)pooledforAustralia.TheRRsforweeks3 + 4
aremoresimilarandsocouldbepooledtogiveanoverall,
international estimate: 1.7 (1.3–2.2).
While the rates of drug-related death during weeks
1 + 2variedconsiderablybetweeneligiblestudies(18–46
per 1000 person-years), the rates during weeks 5–12
were broadly similar: approximately four per 1000
person-years, albeit slightly lower for Washington State.
DISCUSSION
Key ﬁndings
This meta-analysis demonstrated an internationally
high, three- to eightfold increased risk of drug-related
death in the ﬁrst 2 weeks after release from prison com-
pared with the subsequent 10 weeks. There was hetero-
geneity in fatal overdose risk across the three continents
represented, with one US and the two Australian studies
showing a much lower overdose risk in the ﬁrst 2 weeks
post-release than the other US and two UK studies. The
risk of drug-related death is also shown to remain
elevated beyond the ﬁrst 2 weeks post-release into the
second 2 weeks (relative to weeks 5–12). This reinforces
earlier observations [3] [4–6] that, while the risk
decreases by weeks 3 + 4, it remains importantly raised.
Interpretation
The increased risk of drug-related death may be
explained by a decrease in tolerance to drugs as a result
of being in prison where drug use is less frequent and the
drugs may be of lower purity [1]; and there could be
a tendency for ‘celebration’ on release. Across the six
studies the RRs for weeks 1 + 2 are elevated to different
extents, which is perhaps unsurprising given the possible
variations in prisons’ drug policies and in the nature of
illicit drug use more broadly. We highlight here potential
explanations for the differently elevated RRs in the ﬁrst 2
weeks.
The purity of heroin (as well as methampheta-
mines, cocaine and crack cocaine) could vary according
to manufacturing and availability; and associations
between heroin purity and the occurrence of drug-
related deaths have been found [29,30]. The prevalence
of injecting versus non-injecting routes of opioid admin-
istration may vary regionally, and injection poses the
greater overdose risk [31]. There may also be regional
variations in the patterns of co-use of alcohol, benzodi-
azepines and other depressants of the central nervous
system. In combination with heroin, such depres-
sants potentially present an increased overdose risk
[21,30,34].Uponreleasefromprison,regionalvariations
in the above drug use behaviours or cultures could
contribute to differential effects on the immediate risk
of drug-related death, before tolerance is restored.
In addition, drug treatment programmes may differ in
availability, both inside and outside prisons; in metha-
done maintenance dose (>50 mg); and the protection
they afford against injection-related risk behaviours and
premature mortality [32,33].
Studies also varied by the age, sex and length of incar-
ceration of their respective ex-prisoners. The Scottish
study focused upon 15–35-year-old males who had been
Drug-related deaths after release from prison 1549
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Figure 2 Forest plot of relative risks of drug-
related death. (a) In weeks 1–2 versus weeks
3–12.(b) In weeks 1–2 versus weeks 5–12.(c)
In weeks 3–4 versus weeks 5–12; CI: conﬁ-
dence interval
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© 2010 The Authors. Journal compilation © 2010 Society for the Study of Addiction Addiction, 105, 1545–1554incarcerated for at least 14 days, to target the younger,
short sentence proﬁle of drug-users [3]. In Binswanger
et al. [10], two-ﬁfths of released prisoners were outside
this age range; females were included (3967 of 30 237);
and releases were from ‘prisons’ which, by deﬁnition in
the United States, are for individuals sentenced for more
than 1 year (plus those re-incarcerated for violating
parole). To try to identify aspects in correctional policies
or prisoners’ demography that determine their drug-
related death risk soon after release, more studies of the
type included in this meta-analysis from other correc-
tional systems would be needed.
We note that the large, ineligible, last-release histori-
cal study in North Carolina, 1980–2005 [24] yielded a
low relative risk comparing weeks 1 + 2 with weeks
3–12,3.1(95%CI:1.7–5.5).Thiswasinagreementwith
the New Mexico study [10], 3.1 (95% CI: 1.3–7.1), but
considerably lower than the study in Washington State
[9], 8.4 (95% CI: 5.0–14.2). Given that Rosen, Schoen-
bach & Wohl [24] introduced upward bias by studying
ex-prisoners’ most recent incarceration, one might have
expected higher absolute risks to be reported.
The Australian studies [7,8] exhibited the lowest
RR for weeks 1 + 2. One explanatory factor could be
the earlier establishment of methadone maintenance in
NSW prisons (readily available for prisoners from the late
1980s [35] versus from only 2003 in Scotland [36]).
This was tested in an exploratory re-analysis of the NSW
data for consecutive 5-year periods. Unexpectedly, the RR
forweeks1 + 2actuallyincreasedfrom2.7(95%CI:1.7–
4.3) in 1988–92 to 5.1 (95% CI: 3.8–6.9) in 1998–
2002. Of course, temporal analyses are liable to
confounding. Australia’s average heroin purity roughly
trebled during 1996–2000 [37], which may have caused
an increase in overdose fatalities [29]. Moreover, Austra-
lia’s heroin drought at the end of 2000 [38] is well
known for having complicated the interpretation of its
drug-related mortality trends.
Another possible explanation for the observed varia-
tioninriskscouldbestudies’differentdeﬁnitionsof drug-
related death (see Appendix S1). For example, suicides
were excluded from the deﬁnition of drug-related death
adoptedbyBird&Hutchinson[3],butincludedbyFarrell
& Marsden [4–6] and Kariminia et al. [9] (and by Rosen,
Schoenbach & Wohl [24]). The impact of these differing
deﬁnitions was explored by re-analysing the NSW data
accordingtothedeﬁnitionusedbyBird&Hutchinson[3].
This yielded virtually unaltered RRs (data available from
authors), suggesting that different deﬁnitions did not
account for the heterogeneity. Nevertheless, studies’ dif-
ferent deﬁnitions remain an acknowledged limitation of
our meta-analysis.
Inclusion of the study by Verger et al. [27] would have
caused analytical problems because they did not observe
any drug-related deaths in weeks 1 + 2 and only one
in weeks 3–12 after release. Under the null hypothesis
of homogeneity of risk over the 12-week period, the
expectednumbersof suchdeathsinweeks1 + 2wouldbe
so small that the large sample approximation, upon
which the c2 distribution is based, breaks down. In our
view, including such studies does not make statistical
sense and we suggest that meta-analyses more generally
may beneﬁt from the exclusion of such poorly powered
studies from the outset.
This meta-analysis includes only six studies, but each
is moderately powerful and they conform to robust eligi-
bility criteria. As forewarned by Seaman et al. [2], our
12-week follow-up period avoids major confounding by
periodic changes in ex-prisoners’ drug use. The ﬁndings
do not rely on either ex-prisoners’ willingness to self-
identify as drug-using or the diagnosis of drug depen-
dence. Analyses are unbiased and estimates have been
pooled only where appropriate. The meta-analysis was
restricted to studies with associated publications in the
English language, so it is possible that studies in other
languages were missed. However, as the search retrieved
studies from Finland, Denmark and France we hope that
studies omitted by restricting to English-language studies
are few, if any. Further studies from resource-poor coun-
tries and other continents would, however, be highly
instructive.
Futurestudiesof drug-relateddeathsoonafterrelease
fromprisonshouldbewelldesigned,alongthelinesof the
eligibilitycriteriaforthismeta-analysis.Forsufﬁcientsta-
tisticalpower,wesuggestthatstudiesshouldbeof atleast
10 000 index releases (10 000 unique ex-prisoners),
withatleasteightdrug-relateddeathsintheﬁrst2weeks.
Based on the calculations of Bird & Hutchinson [3],
studies of this size would have at least 50% statistical
power to detect a RR of 4 for drug-related death during
weeks 1 + 2 versus weeks 3–12 after release from prison.
Remedial action is required by both prisons and com-
munities to address this observed elevation in risk. Pris-
oners should be alerted to the high risk of overdose death
soon after release, advised not to be alone if they use
drugs and to be wary of mixing heroin with other drugs,
including alcohol [34]. Transitional care programmes,
which provide pre- and post-release treatment and
support, are promising interventions but, as yet, the
research has not been conclusive. Novel programmes
include prison-based education about naloxone (heroin
antidote) and its prescription to prisoners with a history
of heroin injection [3].
CONCLUSION
In conclusion, further research is needed urgently on
mortality after release from prison, as well as interven-
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© 2010 The Authors. Journal compilation © 2010 Society for the Study of Addiction Addiction, 105, 1545–1554tions to reduce the risk of drug-related death during the
transition from prison to the community. At present, the
regional and cultural variations in drug use limit what
canbelearntfromthestrategiesandexperiencesof other
countries around the world. With suitable data from
additional studies, we may be able to identify key charac-
teristics of regions, prisons or prisoners that explain the
variation in the RR of drug-related death soon after
release. Nevertheless, the elevation in risk clearly exists,
and ﬁndings from pharmaceutical experimental studies
of remedial interventions are likely to be transferable
between countries.
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